» Articles » PMID: 31102403

Risk Stratification of Cervical Lesions Using Capture Sequencing and Machine Learning Method Based on HPV and Human Integrated Genomic Profiles

Abstract

From initial human papillomavirus (HPV) infection and precursor stages, the development of cervical cancer takes decades. High-sensitivity HPV DNA testing is currently recommended as primary screening method for cervical cancer, whereas better triage methodologies are encouraged to provide accurate risk management for HPV-positive women. Given that virus-driven genomic variation accumulates during cervical carcinogenesis, we designed a 39 Mb custom capture panel targeting 17 HPV types and 522 mutant genes related to cervical cancer. Using capture-based next-generation sequencing, HPV integration status, somatic mutation and copy number variation were analyzed on 34 paired samples, including 10 cases of HPV infection (HPV+), 10 cases of cervical intraepithelial neoplasia (CIN) grade and 14 cases of CIN2+ (CIN2: n = 1; CIN2-3: n = 3; CIN3: n = 9; squamous cell carcinoma: n = 1). Finally, the machine learning algorithm (Random Forest) was applied to build the risk stratification model for cervical precursor lesions based on CIN2+ enriched biomarkers. Generally, HPV integration events (11 in HPV+, 25 in CIN1 and 56 in CIN2+), non-synonymous mutations (2 in CIN1, 12 in CIN2+) and copy number variations (19.1 in HPV+, 29.4 in CIN1 and 127 in CIN2+) increased from HPV+ to CIN2+. Interestingly, 'common' deletion of mitochondrial chromosome was significantly observed in CIN2+ (P = 0.009). Together, CIN2+ enriched biomarkers, classified as HPV information, mutation, amplification, deletion and mitochondrial change, successfully predicted CIN2+ with average accuracy probability score of 0.814, and amplification and deletion ranked as the most important features. Our custom capture sequencing combined with machine learning method effectively stratified the risk of cervical lesions and provided valuable integrated triage strategies.

Citing Articles

Risk assessment and triage strategy of cervical cancer primary screening on HPV integration status: 5-year follow-up of a prospective cohort study.

Tian X, Weng D, Chen Y, Wang Y, Li X, Wang X J Natl Cancer Cent. 2024; 4(4):311-317.

PMID: 39735440 PMC: 11674434. DOI: 10.1016/j.jncc.2024.08.001.


Analysis of effectiveness in an artificial intelligent film reading system combined with liquid based cytology examination for cervical cancer screening.

Liu D, Chu J Am J Transl Res. 2024; 16(9):4979-4987.

PMID: 39398548 PMC: 11470330. DOI: 10.62347/EVXV1402.


Advancing epigenetic profiling in cervical cancer: machine learning techniques for classifying DNA methylation patterns.

Apoorva , Handa V, Batra S, Arora V 3 Biotech. 2024; 14(11):264.

PMID: 39391214 PMC: 11461404. DOI: 10.1007/s13205-024-04107-2.


Applications of cell therapy in the treatment of virus-associated cancers.

Toner K, McCann C, Bollard C Nat Rev Clin Oncol. 2024; 21(10):709-724.

PMID: 39160243 DOI: 10.1038/s41571-024-00930-x.


Molecular aspects of cervical cancer: a pathogenesis update.

Vallejo-Ruiz V, Gutierrez-Xicotencatl L, Medina-Contreras O, Lizano M Front Oncol. 2024; 14:1356581.

PMID: 38567159 PMC: 10985348. DOI: 10.3389/fonc.2024.1356581.